These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 36042753)

  • 1. A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients.
    Shetty A; Chandrakant NS; Darnule RA; Manjunath BG; Sathe P
    Indian J Crit Care Med; 2022 Aug; 26(8):913-919. PubMed ID: 36042753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
    Liu F; Wang HM; Wang T; Zhang YM; Zhu X
    BMC Infect Dis; 2016 Sep; 16():488. PubMed ID: 27633969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.
    Wu J; Zhou L; Liu J; Ma G; Kou Q; He Z; Chen J; Ou-Yang B; Chen M; Li Y; Wu X; Gu B; Chen L; Zou Z; Qiang X; Chen Y; Lin A; Zhang G; Guan X
    Crit Care; 2013 Jan; 17(1):R8. PubMed ID: 23327199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.
    Mutchnick MG; Lindsay KL; Schiff ER; Cummings GD; Appelman HD; Peleman RR; Silva M; Roach KC; Simmons F; Milstein S; Gordon SC; Ehrinpreis MN
    J Viral Hepat; 1999 Sep; 6(5):397-403. PubMed ID: 10607256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing.
    Bai H; Liang L; Qi X; Xu Y; Liu Y; Ren D; Cai Z; Mao W; Wang X; Qin H; Hu F; Shi B
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110983. PubMed ID: 37769533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Manomaipiboon A; Pholtawornkulchai K; Poopipatpab S; Suraamornkul S; Maneerit J; Ruksakul W; Phumisantiphong U; Trakarnvanich T
    Trials; 2022 Aug; 23(1):714. PubMed ID: 36028897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial.
    Patankar SB; Gorde A; Joshi K; Suryawanshi K; Soni P; Shah T; Patankar S; Jha D; Raje R; Rangnekar H
    J Ayurveda Integr Med; 2022; 13(4):100653. PubMed ID: 36311474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the Unani Regimen as an Add-On to Standard Treatment in Hospitalised RT-PCR-Confirmed Mild to Moderate COVID-19 Patients: An Open-Label Randomized Controlled Trial.
    Kishore J; Kumar R; Nazli T; Ahmad A; Kumar P; Khan AA
    Cureus; 2023 May; 15(5):e38574. PubMed ID: 37284399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.
    Huang C; Fei L; Xu W; Li W; Xie X; Li Q; Chen L
    Front Med (Lausanne); 2021; 8():664776. PubMed ID: 33968969
    [No Abstract]   [Full Text] [Related]  

  • 15. Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.
    Wu M; Ji JJ; Zhong L; Shao ZY; Xie QF; Liu ZY; Wang CL; Su L; Feng YW; Liu ZF; Yao YM
    Int Immunopharmacol; 2020 Nov; 88():106873. PubMed ID: 32795897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19.
    Nicastri E; Marinangeli F; Pivetta E; Torri E; Reggiani F; Fiorentino G; Scorzolini L; Vettori S; Marsiglia C; Gavioli EM; Beccari AR; Terpolilli G; De Pizzol M; Goisis G; Mantelli F; Vaia F; Allegretti M;
    EClinicalMedicine; 2022 Jun; 48():101450. PubMed ID: 35582123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
    Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
    Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.